MedTrace Logo

Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis

NCT07235644 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2025-11-19

No results posted yet for this study

Summary

This observational study investigates if switching from MabThera® to Rixathon® is associated with changes in disease activity and/or safety in people with multiple sclerosis (MS).

The main questions it aims to answer are:

* Does switching to Rixathon® affect tissue damage, measured by blood levels of neurofilament light (pNfL)?
* Does switching to Rixathon® affect the number of new MRI lesions, relapses, or disability progression?

Researchers will look at health information already collected from participants before and after the medication switch. Participants include people with MS treated at Uppsala University Hospital who switched from MabThera® to Rixathon® starting in January 2023. Researchers will use data from regular clinical visits, blood tests, brain MRI scans, and disability scores (EDSS) recorded in the Swedish MS Registry.

Conditions

  • MS (Multiple Sclerosis)
  • Multiple Sclerosis (MS) - Relapsing-remitting
  • Multiple Sclerosis (Relapsing Remitting)

Sponsors & Collaborators

  • Uppsala University

    lead OTHER

Principal Investigators

  • Joachim Burman, MD, PhD · Uppsala University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07235644 on ClinicalTrials.gov